Novel biomarkers assist in detection of liver fibrosis in HCV patients

Abstract Background Accurate staging in individuals infected with hepatitis C is imperative to understand their long-term risk for liver-related complications. Liver biopsy has a traditional role to determine the levels of liver fibrosis specifically in hepatitis C virus patients. However, the devel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tamer A. Addissouky, Yuliang Wang, Fayed Attia Koutb Megahed, Ayman E. El Agroudy, Ibrahim El Tantawy El Sayed, Abdel Moneim A. K. El-Torgoman
Formato: article
Lenguaje:EN
Publicado: SpringerOpen 2021
Materias:
Acceso en línea:https://doaj.org/article/d43205344ee94c458f1abe5fbd6d8336
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract Background Accurate staging in individuals infected with hepatitis C is imperative to understand their long-term risk for liver-related complications. Liver biopsy has a traditional role to determine the levels of liver fibrosis specifically in hepatitis C virus patients. However, the development of non-invasive options has reduced the utilization of biopsy in this population. Main body of the abstract Detecting fibrosis levels through blood samples is already an acceptable alternative to biopsy; however, the optimal non-invasive panel has yet to be defined. Our study indicated hyaluronic acid, collagen oligomeric matrix protein, collagen type IV, and liver fibrosis scoring systems to distinguish fibrosis patients from the non-fibrosis group. Short conclusion The combination of these novel biomarkers, H. A, CO-IV, and Comp tests, could be used to accurately stage individuals with hepatitis C.